Global Prefilled Auto Injectors Market - 2024-2031
The global prefilled auto-injectors market reached US$ YY million in 2023 and is expected to reach US$ YY million by 2031, growing at a CAGR of YY% during the forecast period 2024-2031.
Auto-injectors are the devices that are used to accurately deliver the drug in the patient's body, making drug delivery convenient. There are two types of auto-injectors which are cartridge-based and pre-filled ones. Pre-filled auto-injectors basically contain single doses of drugs that were pre-filled and readily available for administration. Currently, there are several pre-filled auto-injectors approved and commercially sold. The notable examples are EpiPen which is used for the treatment of anaphylaxis, Humira, Rosuvo, Orencia, and SIMPONI for the treatment of several auto-immune conditions. There are several other pre-filled auto-injectors used in migrane and diabetes.
The rising investments in product development, advancements in drug delivery, and rising preference for self-administration of drugs for chronic conditions are the factors that are expected to strongly drive the market growth in the forecast period.
Market Dynamics: Drivers
Rising pipeline development and approval of products
Autoinjectors right from their invention have revolutionized drug delivery, especially the delivery of biopharmaceuticals. These autoinjectors have become a solution for complex problems such as precise dosing, needle phobia, safety in the context of drugs with narrow margin of safety especially biologic drugs, etc. They offer several advantages over conventional drug delivery and have attained greater attention in recent times. Currently, over 300 million pre-filled auto-injectors are sold annually and several companies have been actively focussing on the development of pre-filled auto-injectors for their drugs, some of which have recently got approval for marketing authorization by the regulatory bodies are some are currently in the development phase. This continuous innovation and expansion of the pre-filled auto-injector portfolio is expected to drive the global market in the forecast period.
For instance, in February 2023, the US Food and Drug Administration (FDA) approved Tezspire (tezepelumab) a pre-filled auto-injector developed by AstraZeneca and Amgen. Tezspire is commercially launched in the U.S. for use in severe asthmatic patients.
In December 2023, the U.S. Food and Drug Administration (FDA) approved UDENYCA ONBODY a prefilled auto-injector for the treatment of infections after cancer chemotherapy. UDENYCA is a pegfilgrastim biosimilar approved in the U.S. and has treated approximately 300,000 patients since its launch in 2019.
Also in May 2023, the U.S. Food and Drug Administration (FDA) approved the Cyltezo Pen developed by Boehringer Ingelheim International GmbH. The FDA had already approved Cyltezo (adalimumab-adbm) which is a biosimilar of Humira in the form of a pre-filled syringe and is indicated for the treatment of multiple types of chronic inflammatory conditions.
In addition, factors such as rising preference for self-medication, and rising technological advancements in drug delivery are expected to boost the market growth in the forecast period.
Restraints
The high cost of prefilled auto-injectors is one of the restraining factors that may hinder market growth. Affordability plays a crucial role when a new product should be adopted in the market. Chronic patients in low-middle-income nations may not have access to these advanced drug delivery devices. In addition, patient compliance and adherence issues may pose a significant challenge to the market growth which may cause lower adoption of the devices.
For more details on this report - Request for Sample
Segment Analysis
The global prefilled auto-injectors market is segmented based on application, distribution channel and region.
The autoimmune conditions in the application segment accounted for approximately 45.2% of the global prefilled auto-injectors market share
Autoimmune diseases are those conditions in which the body’s immune system attacks its cells. There are several types of autoimmune conditions and the commonest ones are rheumatoid arthritis, type 1 diabetes, Crohn’s disease, thyroid conditions, psoriasis, etc. There are several drugs that are approved for the treatment of these auto-immune conditions and the notable one is Humira (adalimumab) which is indicated for rheumatoid arthritis, juvenile idiopathic arthritis (JIA), psoriatic arthritis, ankylosing spondylitis, IBD, uveitis etc. Humira is available in single-dose-prefilled auto-injectors. Likewise, several other top-selling prefilled auto-injectors are indicated for the treatment of auto-immune conditions.
Geographical Analysis
North America is expected to dominate the market with a 43.2% share in the global prefilled auto-injectors market
North America is expected to dominate the market due to its well-advanced healthcare infrastructure, and state-of-the-art hospitals equipped with high-end technologies. Moreover, the the major high-income countries in the region the U.S. and Canada are well-known for their investments in the healthcare industry. The majority of the manufacturers of prefilled auto-injectors have a stronghold market share in these regions which is a strong contributing factor to the region’s dominance in the global market.
Market Segmentation
By Application
• Anaphylaxis
• Migraine
• Diabetes
• Orthopedic Conditions
• Autoimmune Conditions
• Others
By Route of Administration
• Subcutaneous
• Intra-Muscular
By Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
By Region
• North America
U.S.
Canada
Mexico
• Europe
Germany
U.K.
France
Spain
Italy
Rest of Europe
• South America
Brazil
Argentina
Rest of South America
• Asia-Pacific
China
India
Japan
South Korea
Rest of Asia-Pacific
• Middle East and Africa
Competitive Landscape
The major players in the prefilled auto-injectors market include Teva Pharmaceuticals USA, Inc., Viatris Inc., Medexus Pharma, Inc., ALK-Abelló Ltd, Novo Nordisk A/S, Bausch Health, Canada Inc., GSK plc., Eli Lilly and Company, AbbVie. and UCB, Inc. among others.
Why Purchase the Report??
• To visualize the global prefilled auto-injectors market segmentation based on application, route of administration, distribution channel and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development
• Excel data sheet with numerous data points of prefilled auto-injectors market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.
The global prefilled auto-injectors market report would provide approximately 62 tables, 54 figures, and 187 Pages.
Target Audience 2024
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies
- 1. Methodology and Scope
- 1.1. Research Methodology
- 1.2. Research Objective and Scope of the Report
- 2. Definition and Overview
- 3. Executive Summary
- 3.1. Snippet by Application
- 3.2. Snippet by Route of Administration
- 3.3. Snippet by Distribution Channel
- 4. Dynamics
- 4.1. Impacting Factors
- 4.1.1. Drivers
- 4.1.1.1. Rising pipeline development and approval of products
- 4.1.1.2. Rising technological advancements in the drug delivery
- 4.1.2. Restraints
- 4.1.2.1. High cost of pre-filled auto-injectors
- 4.1.3. Opportunity
- 4.1.4. Impact Analysis
- 5. Industry Analysis
- 5.1. Porter's Five Force Analysis
- 5.2. Supply Chain Analysis
- 5.3. Pricing Analysis
- 5.4. Regulatory Analysis
- 5.5. Unmet Needs
- 5.6. PESTEL Analysis
- 5.7. Patent Analysis
- 5.8. SWOT Analysis
- 6. COVID-19 Analysis
- 6.1. Analysis of COVID-19
- 6.1.1. Scenario Before COVID
- 6.1.2. Scenario During COVID
- 6.1.3. Scenario Post COVID
- 6.2. Pricing Dynamics Amid COVID-19
- 6.3. Demand-Supply Spectrum
- 6.4. Government Initiatives Related to the Market During Pandemic
- 6.5. Manufacturers Strategic Initiatives
- 6.6. Conclusion
- 7. By Application
- 7.1. Introduction
- 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 7.1.2. Market Attractiveness Index, By Application
- 7.2. Anaphylaxis*
- 7.2.1. Introduction
- 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 7.3. Migraine
- 7.4. Diabetes
- 7.5. Orthopedic Conditions
- 7.6. Autoimmune Conditions
- 7.7. Others
- 8. By Route of Administration
- 8.1. Introduction
- 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
- 8.1.2. Market Attractiveness Index, By Route of Administration
- 8.2. Subcutaneous*
- 8.2.1. Introduction
- 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 8.3. Intramuscular
- 9. By Distribution Channel
- 9.1. Introduction
- 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 9.1.2. Market Attractiveness Index, By Distribution Channel
- 9.2. Hospital Pharmacies*
- 9.2.1. Introduction
- 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 9.3. Retail Pharmacies
- 9.4. Online Pharmacies
- 10. By Region
- 10.1. Introduction
- 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
- 10.1.2. Market Attractiveness Index, By Region
- 10.2. North America
- 10.2.1. Introduction
- 10.2.2. Key Region-Specific Dynamics
- 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
- 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
- 10.2.6.1. The U.S.
- 10.2.6.2. Canada
- 10.2.6.3. Mexico
- 10.3. Europe
- 10.3.1. Introduction
- 10.3.2. Key Region-Specific Dynamics
- 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
- 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
- 10.3.6.1. Germany
- 10.3.6.2. UK
- 10.3.6.3. France
- 10.3.6.4. Italy
- 10.3.6.5. Spain
- 10.3.6.6. Rest of Europe
- 10.4. South America
- 10.4.1. Introduction
- 10.4.2. Key Region-Specific Dynamics
- 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
- 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
- 10.4.6.1. Brazil
- 10.4.6.2. Argentina
- 10.4.6.3. Rest of South America
- 10.5. Asia-Pacific
- 10.5.1. Introduction
- 10.5.2. Key Region-Specific Dynamics
- 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
- 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
- 10.5.6.1. China
- 10.5.6.2. India
- 10.5.6.3. Japan
- 10.5.6.4. South Korea
- 10.5.6.5. Rest of Asia-Pacific
- 10.6. Middle East and Africa
- 10.6.1. Introduction
- 10.6.2. Key Region-Specific Dynamics
- 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
- 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 11. Competitive Landscape
- 11.1. Competitive Scenario
- 11.2. Market Positioning/Share Analysis
- 11.3. Mergers and Acquisitions Analysis
- 12. Company Profiles
- 12.1. Teva Pharmaceuticals USA, Inc.
- 12.1.1. Company Overview
- 12.1.2. Product Portfolio and Description
- 12.1.3. Financial Overview
- 12.1.4. Key Developments
- 12.2. Viatris Inc.
- 12.3. Medexus Pharma, Inc.
- 12.4. ALK-Abelló Ltd
- 12.5. Novo Nordisk A/S
- 12.6. Bausch Health, Canada Inc.
- 12.7. GSK plc.
- 12.8. Eli Lilly and Company
- 12.9. AbbVie.
- 12.10. UCB, Inc.
- LIST NOT EXHAUSTIVE
- 13. Appendix
- 13.1. About Us and Services
- 13.2. Contact Us
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook